Psilocybine services in Oregon: a call for awareness among clinical toxicologists

Abstract

Background

In 2023, Oregon enacted laws regulating the manufacture and use of psilocybine products in licensed facilities for supervised sessions with trained facilitators.

Commentary

This commentary summarizes the final rules for psilocybine services in Oregon, and provides perspectives from a clinical toxicologist on some of the issues that may arise. These include the scope of practice for non-clinical facilitators, prevention and management of adverse drug reactions, and toxicological uncertainties with regards to dose considerations for people with mental health and other medical conditions.

Conclusion

This commentary addresses some common misperceptions relating to the program, and provides perspective on some of the challenges that clinical toxicologists may encounter as legislative reform initiatives for psilocybine move forward throughout the United States.

Keywords:

• Psilocybine
• psychedelic
• toxicology
• adverse event
• public health

Correction Statement

This article has been corrected with minor changes. These changes do not impact the academic content of the article.

Disclosure statement

No potential conflict of interest was reported by the author.

Additional information

Funding

The author reported there is no funding associated with the work featured in this article.